Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?

American journal of medical genetics - 17 Sept 1999

Enns G M, Roeder E, Chan R T, Ali-Khan Catts Z, Cox V A, Golabi M

Abstract excerpt

Cyclophosphamide (CP) is an alkylating agent widely used in treating cancer and autoimmune disease. CP is classified as a pregnancy risk factor D drug and is teratogenic in animals, but population studies have not conclusively demonstrated teratogenicity in humans. Six isolated reports of prenatally exposed infants with various congenital anomalies exist, but to date no specific phenotype has been delineated. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blepharophimosis
Share to Craniosynostoses
Share to Cyclophosphamide

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Ear, External

Share to Limb Deformities, Congenital

Share to Maternal-Fetal Exchange

Share to Pregnancy Complications

Share to Teratogens

Source

Identifiers

PMID: 10482872

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?PMID 10482872Read ↗

Cyclophosphamide, methotrexate, and cytarabine embropathy: Is apoptosis the common pathway?Semantic proximity Read ↗

Methimazole embryopathy: a contribution to defining the phenotype.Semantic proximity Read ↗

In utero exposure to mycophenolate mofetil: a characteristic phenotype?Semantic proximity Read ↗

Methimazole embryopathy: delineation of the phenotype.Semantic proximity Read ↗

A case of methotrexate embryopathy with holoprosencephaly, expanding the phenotype.Semantic proximity Read ↗

Paracetamol (N-acetyl-para-aminophenol) disrupts early human embryogenesisSemantic proximity Read ↗

Warfarin-Induced Developmental Toxicity: Insights into Embryogenesis, Teratogenicity, and Molecular PathwaysSemantic proximity Read ↗

Human teratogens and genetic phenocopies. Understanding pathogenesis through human genes mutation.Semantic proximity Read ↗

An additional patient with mycophenolate mofetil embryopathy: cardiac and facial analyses.Semantic proximity Read ↗

Carbimazole/methimazole embryopathy in siblings: a possible genetic susceptibility.Semantic proximity Read ↗

Parietal bone agenesis and athelia in retinoic acid embryopathy: An expansion of the phenotype.Semantic proximity Read ↗

Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.